Ads
related to: breast cancer molecular targeted therapy impact factor
Search results
Results From The WOW.Com Content Network
As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, [2] rather than by simply interfering with all rapidly dividing cells (e.g. with traditional chemotherapy).
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang ( UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer , including medicinal chemistry , pharmacology , molecular biology , genomics , and ...
It is targeted towards a wide audience of clinical researchers, epidemiologists, immunologists, or cell biologists interested in breast cancer. The types of articles in this journal include original research, invited reviews, discussions on controversial issues, book reviews, meeting reports, letters to the editors, and editorials.
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Therapies with specific molecular or genetic targets, which inhibit growth-promoting signals from classic endocrine hormones (primarily estrogens for breast cancer and androgens for prostate cancer), are now called hormonal therapies. Other inhibitions of growth-signals, such as those associated with receptor tyrosine kinases, are targeted therapy.
Molecular Cancer is a peer-reviewed open-access scientific journal covering all aspects of cancer research. The journal is published by BioMed Central and was established in 2002. The first editor-in-chief was Chi V. Dang, who is also the scientific director of the Ludwig Institute for Cancer Research . [ 1 ]
Ads
related to: breast cancer molecular targeted therapy impact factor